Ad hoc announcement pursuant to Art. 53 LR April 25, 2025 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2025, which covers the results of its business activities for the first three months of 2025. Based on the consolidated accounts of BB Biotech AG, net loss for  [ … ]

Media release as at April 25, 2025 BB Biotech Q1 2025: Sharpened portfolio focus amid continued market volatility The first quarter of 2025 was marked by elevated market volatility and rising macro uncertainty, driven by geopolitical developments and trade tensions. Biotech valuations, especially in small- and mid-cap names, remained under pressu [ … ]

Media release of March 19, 2025 Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today. Shareholders voted in favor of the proposal to pay out a divi [ … ]

Ad hoc announcement pursuant to Art. 53 LR February 21, 2025 Annual report of BB Biotech AG as at December 31, 2024  BB Biotech AG publishes its 2024 annual report BB Biotech AG published its annual report for fiscal year 2024 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi [ … ]

Media release as at February 21, 2025 Annual Report 2024: BB Biotech positions for structural sector recovery amid shifting market dynamics 2024, especially the fourth quarter, signaled the early stage of a structural recovery in biotech, driven by renewed investor focus on clinical data, regulatory approvals, and commercial execution. BB Biotec [ … ]

Media release as of January 24, 2025 BB Biotech: Preliminary full-year 2024 results and dividend proposal BB Biotech AG reports the following preliminary and unaudited figures for 2024: Full-year 2024: BB Biotech shares delivered a total return of -13.5% in CHF and -14.1% in EUR (including the CHF 2.00 dividend paid in March 2024). NAV performan [ … ]

Ad hoc announcement pursuant to Art. 53 LR January 24, 2025 BB Biotech AG closes the 2024 fiscal year with a profit In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information: Based on its preliminary unaudited consolidated figures, BB Biotech AG reports a profit of approximately [ … ]

  London, UK, 22 January 2025   Edison issues report on BB Biotech (BION) Edison issues report on BB Biotech (BION). BB Biotech (BION) is the largest biotech investor among its investment company peers. The company is focused on achieving long-term capital growth by investing in high-quality biotech assets developing and marketing innovative d [ … ]